14594-6 |
Amitriptyline+Nortriptyline |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
Amitriptyline+Nortriptyline [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14594-6 |
|
|
|
|
Both |
|
|
|
0 |
Amitrip+Nor Gast Ql |
|
|
|
|
|
Amit; Amitrip; Amitrip+Nor; Amitriptylene; Amitriptyline metabolite; Amitriptyln; Aventyl; DRUG/TOXICOLOGY; Drugs; Elatrol; Elavil; Endep; GAST; Gastric contents; Gastric fluid; Nortrip; Nortriptylene; Nortriptyln; Ordinal; Pamelor; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Trepiline; Tryptanol; Tryptizol |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14595-3 |
Amitriptyline+Nortriptyline |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Amitriptyline+Nortriptyline [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14595-3 |
|
|
|
|
Both |
|
|
|
0 |
Amitrip+Nor SerPl Ql |
|
|
|
|
|
Amit; Amitrip; Amitrip+Nor; Amitriptylene; Amitriptyline metabolite; Amitriptyln; Aventyl; DRUG/TOXICOLOGY; Drugs; Elatrol; Elavil; Endep; Nortrip; Nortriptylene; Nortriptyln; Ordinal; Pamelor; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Trepiline; Tryptanol; Tryptizol |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14596-1 |
Amitriptyline+Nortriptyline |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Amitriptyline+Nortriptyline [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
14596-1 |
|
|
|
|
Both |
|
|
|
0 |
Amitrip+Nor Ur Ql |
|
|
|
|
|
Amit; Amitrip; Amitrip+Nor; Amitriptylene; Amitriptyline metabolite; Amitriptyln; Aventyl; DRUG/TOXICOLOGY; Drugs; Elatrol; Elavil; Endep; Nortrip; Nortriptylene; Nortriptyln; Ordinal; Pamelor; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Trepiline; Tryptanol; Tryptizol; UA; UR; Urn |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14597-9 |
Amitriptyline |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Amitriptyline [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14597-9 |
|
|
|
|
Both |
|
|
|
0 |
Amitrip SerPl-sCnc |
|
|
|
Y |
|
Amit; Amitrip; Amitriptylene; Amitriptyln; DRUG/TOXICOLOGY; Drugs; Elatrol; Elavil; Endep; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Trepiline; Tryptanol; Tryptizol |
2.34 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14598-7 |
Amitriptyline+Nortriptyline |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Amitriptyline+Nortriptyline [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14598-7 |
|
|
|
|
Both |
|
|
|
0 |
Amitrip+Nor SerPl-sCnc |
|
|
|
Y |
|
Amit; Amitrip; Amitrip+Nor; Amitriptylene; Amitriptyline metabolite; Amitriptyln; Aventyl; DRUG/TOXICOLOGY; Drugs; Elatrol; Elavil; Endep; Level; Nortrip; Nortriptylene; Nortriptyln; Pamelor; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Trepiline; Tryptanol; Tryptizol |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14599-5 |
Ammonium |
PrThr |
Calculus |
Pt |
Ord |
|
|
ACTIVE |
Ammonium [Presence] in Stone |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
14599-5 |
|
|
|
|
Both |
|
|
|
0 |
Ammonium Stone Ql |
|
|
|
|
|
Amm; Ammon; Calc; Calculi; Chemistry; NH4; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stn; Stone; Stones |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
146-1 |
Cefuroxime.parenteral |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Cefuroxime Parenteral [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
146-1 |
|
Agar diffusion |
|
|
Observation |
|
|
|
0 |
Cefuroxime Parenter Islt KB |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; c308; C33; Ceftin; Cefuroxime Axetil; Cefuroxime Parenter; Cefuroxime Sodium; Curoxim; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kefurox; Kirby-bauer; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Ultroxim; Zinacef |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
1460-5 |
Cobalamins^post dose cyanocobalamin |
MRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Cobalamin (Vitamin B12) [Mass/time] in 24 hour Urine --post dose cyanocobalamin |
|
MIN |
DefinitionDescription |
|
|
mg/24 H |
|
|
|
|
|
|
CHAL |
|
1460-5 |
|
|
|
|
Observation |
|
|
|
0 |
Vit B12 p B12 24h Ur-mRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; After; c133; C721; Cbl; CHEMISTRY.CHALLENGE TESTING; CN-Cbl; Cobalamin; Mass rate; mRate; p B12; p dose; PST; QNT; Quan; Quant; Quantitative; Schilling test; Schillings test; UA; UR; Urn; Vit B12; Vitamin B12 |
2.42 |
1 |
|
|
|
|
|
|
|
mg/(24.h) |
|
|
|
0 |
14600-1 |
Amoxapine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Amoxapine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14600-1 |
|
|
|
|
Both |
|
|
|
0 |
Amoxapine SerPl-sCnc |
|
|
|
Y |
|
Amox; Asendin; Defanyl; Demolox; DRUG/TOXICOLOGY; Drugs; Level; Moxadil; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.34 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14601-9 |
Amoxapine+8-Hydroxyamoxapine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Amoxapine+8-Hydroxyamoxapine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14601-9 |
|
|
|
|
Both |
|
|
|
0 |
Amoxapine+8OH-Amox SerPl-sCnc |
|
|
|
Y |
|
8-Hydroxy amoxapine; 8OH-Amoxapine; Amox; Amoxapine metabolite; Amoxapine+8OH-Amox; Asendin; Defanyl; Demolox; DRUG/TOXICOLOGY; Drugs; Level; Moxadil; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.4 |
1.0k |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
14602-7 |
Amoxapine+8-Hydroxyamoxapine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Amoxapine+8-Hydroxyamoxapine [Molecules/volume] in Serum or Plasma |
|
DEL |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
14602-7 |
|
|
|
|
|
|
|
|
0 |
Deprecated Amoxapine+8OH-Amox SerPl-sCnc |
|
|
|
|
|
8-Hydroxy amoxapine; 8OH-Amoxapine; Amox; Amoxapine metabolite; Amoxapine+8OH-Amox; Asendin; Defanyl; Demolox; DRUG/TOXICOLOGY; Drugs; Level; Moxadil; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.36 |
1.0k |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
14603-5 |
Androstenedione |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHEM |
|
14603-5 |
|
|
|
|
Both |
|
|
|
0 |
Androst SerPl-sCnc |
|
|
|
Y |
|
Chemistry; gamma-4-Androstenedione; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
14604-3 |
Blood group antibodies |
Prid |
Ser/Plas^BPU |
Pt |
Nom |
|
|
ACTIVE |
Blood group antibodies identified in Serum or Plasma from Blood product unit |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
14604-3 |
|
|
|
|
Observation |
|
|
|
0 |
Blood group antibodies SerPl BPU |
|
|
|
|
|
BLOOD BANK; Blood product unit; Blood Product Unit (Pack); Identity or presence; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPl^bpu; SerPlas; Serum; Serum or plasma; SR |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
14605-0 |
Blood group antibodies |
Prid |
Ser/Plas^Donor |
Pt |
Nom |
|
|
ACTIVE |
Blood group antibodies identified in Serum or Plasma from Donor |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
14605-0 |
|
|
|
|
Observation |
|
|
|
0 |
Blood group antibodies SerPl Donr |
|
|
|
|
|
BLOOD BANK; Donr; Identity or presence; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
14606-8 |
Blood group antibody |
PrThr |
Ser/Plas |
Pt |
Ord |
Blood group antibody screen.Prewarmed |
|
ACTIVE |
Blood group antibody screen [Presence] in Serum or Plasma by Prewarmed |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
14606-8 |
|
Blood group antibody screen.Prewarmed |
|
|
Observation |
|
|
|
0 |
Bld gp Ab Scn SerPl Ql Pwarm |
|
|
|
|
|
Ab; Bld gp Ab Scn; BLOOD BANK; Ordinal; Pl; Plasma; Plsm; Point in time; PR; Pwarm; Ql; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: Screen should be omitted from Component. It should be in Method.; Previous Releases: The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14607-6 |
Nuclear Ab |
PrThr |
Body fld |
Pt |
Ord |
|
|
ACTIVE |
Nuclear Ab [Presence] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
14607-6 |
|
|
|
|
Both |
|
|
|
0 |
ANA Fld Ql |
|
|
|
|
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Fl; Fld; FLU; Fluid; NA; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14608-4 |
Nuclear Ab |
PrThr |
Plr fld |
Pt |
Ord |
|
|
ACTIVE |
Nuclear Ab [Presence] in Pleural fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
14608-4 |
|
|
|
|
Both |
|
|
|
0 |
ANA Plr Ql |
|
|
|
|
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; Lung; NA; Nuc; Ordinal; Pleural; Pleural fluid; Point in time; PR; Pulmonary; Pulmonology; Ql; Qual; Qualitative; Random; Respiratory; Screen; Serology; thoracentesis fluid |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14609-2 |
Nuclear Ab |
PrThr |
Periton fld |
Pt |
Ord |
|
|
ACTIVE |
Nuclear Ab [Presence] in Peritoneal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
14609-2 |
|
|
|
|
Both |
|
|
|
0 |
ANA Prt Ql |
|
|
|
|
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Ascites; Ascitic fluid; Ascitis; Autoantibodies; Autoantibody; NA; Nuc; Ordinal; Peritoneal fluid; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
1461-3 |
Epinephrine^1H post 300 ug cloNIDine PO |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
EPINEPHrine [Mass/volume] in Plasma --1 hour post 300 ug cloNIDine PO |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
1461-3 |
|
|
|
|
Observation |
|
|
|
0 |
Epineph 1h p 300 ug CLN PO Plas-mCnc |
|
|
|
Y |
|
1 hour; 1.0Hr; 1h p 300 ug CLN PO; 60 min; 60 minutes; 60M; 60min; Adrenalin; Adrenaline; Adreneline; After; Catapres; CHEMISTRY.CHALLENGE TESTING; E; Epi; Epin; Epinep; Epineph; Epinphrine; Eppi; Level; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random |
2.73 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
14610-0 |
Nuclear Ab |
PrThr |
Synv fld |
Pt |
Ord |
|
|
ACTIVE |
Nuclear Ab [Presence] in Synovial fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
14610-0 |
|
|
|
|
Both |
|
|
|
0 |
ANA Snv Ql |
|
|
|
|
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; Joint aspirate; Joint fld; Joint flu; Joint fluid; NA; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Rheum; Rheumatology; Screen; Serology; SF; SNV; Syn; Syn fl; Synov; Synovial fluid |
2.56 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
14611-8 |
Nuclear Ab pattern |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Nuclear Ab pattern [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
14611-8 |
|
|
|
|
Both |
|
|
|
0 |
ANA Pat Ser-Imp |
|
|
|
|
|
ABS; Aby; ANA; ANA Pat; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; NA; Nominal; Nuc; Point in time; Random; Serology; Serum; SR |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
14612-6 |
Nuclear Ab |
Titr |
Pericard fld |
Pt |
SemiQn |
|
|
ACTIVE |
Nuclear Ab [Titer] in Pericardial fluid |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
14612-6 |
|
|
|
|
Both |
|
|
|
0 |
ANA Titr Pcar |
|
|
|
Y |
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; Cardio; Cardiology; Dilution factor; Dilution Factor (Titer); Heart Disease; NA; Nuc; PCAR; Pericardial Fluid; Point in time; Random; Serology; SmQn; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
14613-4 |
Nuclear Ab |
Titr |
Body fld |
Pt |
SemiQn |
|
|
ACTIVE |
Nuclear Ab [Titer] in Body fluid |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
14613-4 |
|
|
|
|
Both |
|
|
|
0 |
ANA Titr Fld |
|
|
|
Y |
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Dilution factor; Dilution Factor (Titer); Fl; Fld; FLU; Fluid; NA; Nuc; Point in time; Random; Serology; SmQn; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
14614-2 |
Nuclear Ab |
Titr |
Plr fld |
Pt |
SemiQn |
|
|
ACTIVE |
Nuclear Ab [Titer] in Pleural fluid |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
14614-2 |
|
|
|
|
Both |
|
|
|
0 |
ANA Titr Plr |
|
|
|
Y |
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); Lung; NA; Nuc; Pleural; Pleural fluid; Point in time; Pulmonary; Pulmonology; Random; Respiratory; Serology; SmQn; thoracentesis fluid; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
14615-9 |
Nuclear Ab |
Titr |
Periton fld |
Pt |
SemiQn |
|
|
ACTIVE |
Nuclear Ab [Titer] in Peritoneal fluid |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
14615-9 |
|
|
|
|
Both |
|
|
|
0 |
ANA Titr Prt |
|
|
|
Y |
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Ascites; Ascitic fluid; Ascitis; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); NA; Nuc; Peritoneal fluid; Point in time; Prt; Random; Serology; SmQn; Titer; Titered; Titre; Ttr |
2.75 |
1.0k |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |